Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II, Open-Label, Multi-Center Study Evaluating the Safety and Efficacy of Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Next Previous
Trial Profile

A Phase I/II, Open-Label, Multi-Center Study Evaluating the Safety and Efficacy of Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cytarabine/daunorubicin (Primary) ; Ruxolitinib (Primary) ; Stem cell therapies
  • Indications Acute myeloid leukaemia; Essential thrombocythaemia; Myelofibrosis; Myeloproliferative disorders; Polycythaemia vera
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 15 Sep 2025 Status changed from active, no longer recruiting to completed.
  • 02 Apr 2025 Planned End Date changed from 31 Dec 2024 to 30 Jun 2025.
  • 02 Apr 2025 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top